-
Fennec Pharmaceuticals NasdaqCM:FENC Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
Location: 68 TW Alexander Drive, 68 Tw Alexander Dr, Research Triangle Park, NC, 27709, United States | Website: https://fennecpharma.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
220.4M
Cash
22.68M
Avg Qtr Burn
-4.096M
Short % of Float
10.52%
Insider Ownership
16.27%
Institutional Own.
57.51%
Qtr Updated
03/31/25
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
PEDMARK™ (sodium thiosulfate) Details Hearing loss | Approved Quarterly sales |